Progress in Medicinal Chemistry - Reihe herausgegeben von Lawton, G. / Witty, D.R.
129,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
65 °P sammeln
  • Gebundenes Buch

Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, 'validation' of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: _ HIV integrase (discovery of the first-in-class inhibitor drug raltegravir)_ 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, 'validation' of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: _ HIV integrase (discovery of the first-in-class inhibitor drug raltegravir)_ 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation)_ Nicotinic a7 choline receptor (agonists and positive allosteric modulators). _ Bradykinin receptor (new approach to pain therapy)_ Histone deacetylase (new drugs for cancer)_ 5-HT2c receptor modulators (various CNS indications)
Autorenporträt
Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.
From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines.

Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities.

Geoff serves on the Board of Antabio, a French biotech company developing tomorrow's antibacterial drugs.

He is a founder of INMedD, a new medicines discovery social enterprise.